Corton Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Corton Capital’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-62,491	Closed	-$412K	–	602
2024 Q3	$412K	Buy	62,491 +48,399	+343%	+$347K	0.2%	95
2024 Q2	$106K	Buy	+14,092	New	+$123K	0.06%	450
2023 Q3	–	Sell	-19,801	Closed	-$148K	–	523
2023 Q2	$148K	Sell	19,801 -12,860	-39%	-$90K	0.07%	365
2023 Q1	$218K	Buy	+32,661	New	+$259K	0.15%	219
2022 Q3	–	Sell	-16,598	Closed	-$135K	–	357
2022 Q2	$135K	Buy	+16,598	New	+$111K	0.13%	261

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

MIC

Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Corton Capital's RXRX Position: Q4 2024 in Review

Corton Capital sold out of Recursion Pharmaceuticals (RXRX) in Q4 2024, closing a stake of 62,491 shares — an estimated $412K sold.

Corton Capital first reported a position in RXRX in Q2 2022 and held it in 5 quarters. The position peaked at $412K in Q3 2024. 316 funds tracked by Wall St. Rank hold RXRX as of Q4 2024.

Corton Capital reported no remaining Recursion Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Corton Capital sold 62,491 Recursion Pharmaceuticals shares in Q4 2024, an estimated $412K.
Corton Capital first reported a position in Recursion Pharmaceuticals in Q2 2022 and held it in 5 quarters.
Corton Capital's Recursion Pharmaceuticals position peaked at $412K in Q3 2024.
316 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2024.

Based on Corton Capital's 13F filing for Q4 2024, filed 14 Feb 2025.